MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Dirk Schadendorf(Essen University Hospital), Carola Berking(Ludwig-Maximilians-Universität München), Sanjiv S. Agarwala(St. Luke's University Health Network), Carla M.L. van Herpen(Radboud University Medical Center), Paola Queirolo(Ospedale Policlinico San Martino), Christian U. Blank(Dutch Cancer Society), Axel Hauschild(University of Lübeck), J. Thaddeus Beck(Highlands Oncology Group), Annie St‐Pierre(Novartis (Switzerland)), Faiz Niazi(Novartis (Switzerland)), Simon Wandel(Novartis (Switzerland)), Malte Peters(Novartis (Switzerland)), Angela Zubel(Novartis (Switzerland)), Reinhard Dummer(University Hospital of Zurich)
Cited by 643
Abstract
Related Papers
No related papers found
Powered by citation graph analysis